Madrigal’s strategy of pursuing combination therapies while the market remains in its infancy could intrinsically link its ...

GSK touted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

ThermoFisher expects revenue growth in the 3-6% range for 2026 and 2027, and a growth rate of 7% or more in 2028 and beyond.

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

SciNeuro Pharmaceuticals has announced a global licensing and collaboration agreement with Novartis to develop SciNeuro’s ...

AbbVie is now one of 16 big pharma companies to sign MFN deals with the Trump administration and commit to the expansion of ...

Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

Elevidys’ sales missed Q4 analyst estimates, though Sarepta’s CEO Douglas Ingram is confident of a more stable 2026 for the ...

J&J bolstered their pipeline with new deals in 2025. Michael Vi via Shutterstock.com. CEO Joaquin Duato presented a strong ...

At the 44 th Annual J.P. Morgan Healthcare Conference, Sanofi’s growth and projection for 2026 up until the end of the decade ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.